Lundbeck drug gains Canadian approval for the treatment of depression  

The Canadian health authorities have approved Lundbeck's drug Cipralex for the treatment of depression

The Canadian health authorities have approved Lundbeck's drug Cipralex [escitalopram oxalate, called Lexapro in North America - Ed] for the treatment of depression. Marketing of Cipralex in Canada will commence early next year. Stig Løkke Pedersen, executive vice president of Lundbeck says that the company's Canadian organisation has extensive market experience, and the launch of Cipralex will further strengthen Lundbeck's position.


Since its launch in 2002, Cipralex has been introduced in more than 60 countries worldwide. According to IMS Global Learning Consortium, the depression treatment market in Canada was worth DKK 3.6 bn (USD 648 mn) in 2003. The news is reported by net newspaper Infopaq and on Lundbeck's website.


Lundbeck is headquartered in Copenhagen and employs approx. 5,000 people. The pharmaceutical company is engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2003, the company generated revenues of DKK 9.9 bn (USD 1.8 bn).


Link > Lundbeck 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×